JNJ
stock Healthcare Drug Manufacturers - GeneralOverall Healthy · 69%
- Fundamentals Strong
- Trajectory Climbing
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Mixed 3 of 5 trend signals bullishRSI 41 — soft momentum, not yet oversold.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $223.60
- +0.32%
- Close
- $223.60
- +0.32%
- Current
- $223.60
- Prev close
- $222.89
- Today
- 4.57M
- 3-mo avg
- 7.60M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 1498 days ago
- Next expected
- Jul 156 days ago
Recent earnings dates
- Apr 14 98 days ago
- Jan 21 181 days ago
- Oct 14, 2025 280 days ago
- Jul 16, 2025 370 days ago
Past earnings dates come from JNJ’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 53d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), JNJ’s fundamentals read as strong overall.
At 25.9x, investors are paying up; a fair amount of future growth is already in the price.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 2.3% yield is a healthy, generally sustainable level of cash income.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 28.5% margin is strong; the company keeps a healthy slice of every revenue dollar.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 32.9% return on equity is strong; the company compounds owners' capital well.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 13.5% return on assets is strong; the company squeezes good profit from its assets.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 1.44, the company carries a moderate, manageable amount of debt.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.03, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 6.0% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 90.6% from the prior year: strong profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 53d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $82.6B | $78.7B | $85.2B | $88.8B | $94.2B |
| Net income | $14.7B | $20.9B | $35.2B | $14.1B | $26.8B |
| Diluted EPS | $5.51 | $7.81 | $13.72 | $5.79 | $11.03 |
| Dividend / share | $3.98 | $4.19 | $4.70 | $4.91 | $5.14 |
| Total assets | $174.9B | $182.0B | $167.6B | $180.1B | $199.2B |
| Total liabilities | $111.6B | $108.0B | $98.8B | $108.6B | $117.7B |
| Shareholder equity | $63.3B | $74.0B | $76.8B | $71.5B | $81.5B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.4B | $22.5B | $22.5B | $21.9B | $23.7B | $24.0B | $24.6B | $24.1B |
| Net income | $4.7B | $2.7B | $3.4B | $11.0B | $5.5B | $5.2B | $5.1B | $5.2B |
| Diluted EPS | $1.93 | $1.11 | $1.41 | $4.54 | $2.29 | $2.12 | $2.08 | $2.14 |
| Dividend / share | $1.24 | $1.24 | $1.24 | $1.24 | $1.30 | $1.30 | $1.30 | $1.30 |
Leadershipsynced from SEC 59d ago
- Duato Joaquin CEO and Chairman of the Board · Director
- Wolk Joseph J Exec VP, CFO
- Broadhurst Vanessa EVP, Global Corp Affairs
- Decker Robert J VP Corporate Controller
- Forminard Elizabeth EVP, Chief Legal Officer
- Mulholland Kristen EVP, Chief HR Officer
- Reed John C EVP, Innovative Medicine, R&D
- Schmid Timothy EVP, WW Chair, MedTech
- Swanson James D. EVP, CIO
- Taubert Jennifer L EVP, WWC. Innovative Medicine
- Wengel Kathryn E EVP, Chief TO and Risk Officer
- Beckerle Mary C Director
- Doudna Jennifer A Director
- Hewson Marillyn A Director
- Johnson Paula A Director
- Joly Hubert Director
- Mcclellan Mark B. Director
- Morikis John G Director
- Pinto Daniel E Director
- Weinberger Mark A Director
- West Nadja Director
- Woods Eugene A. Director
Officers and board are drawn from JNJ’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- Dec 28, 2025 FY2025 net income +91% YoY
- Sep 9, 2025 Officer or director change reported in an 8-K
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Dividendssynced from Yahoo 52d ago
- 2025 total
- $5.14
- 2026 so far
- $2.642 payments
- 2026 projected
- $5.28+2.7% vs 2025
Projection scales JNJ’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.
Payment history
- May 26 $1.34
- Feb 24 $1.30
- Nov 25, 2025 $1.30
- Aug 26, 2025 $1.30
- May 27, 2025 $1.30
- Feb 18, 2025 $1.24
- Nov 26, 2024 $1.24
- Aug 27, 2024 $1.24
- May 20, 2024 $1.24
- Feb 16, 2024 $1.19
- Nov 20, 2023 $1.19
- Aug 25, 2023 $1.19
- May 22, 2023 $1.19
- Feb 17, 2023 $1.13
- Nov 21, 2022 $1.13
- Aug 22, 2022 $1.13
- May 23, 2022 $1.13
- Feb 18, 2022 $1.06
- Nov 22, 2021 $1.06
- Aug 23, 2021 $1.06
Recent SEC filingssynced from SEC 53d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report